Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 16/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3601288 | 1.00 | AR (1.00) | AR | |
| SCHEMBL3593021 | 1.00 | AR (1.00) | AR | |
| SCHEMBL3610710 | 1.00 | AR (1.00) | AR | |
| SCHEMBL3603759 | 1.00 | AR (1.00) | AR | |
| Sulfuric Acid SCHEMBL3606377 | 0.94 | AR (0.88) | AR | |
| SCHEMBL3592331 | 0.93 | AR (0.86) | AR | |
| SCHEMBL3604603 | 0.84 | AR (0.72) | AR | |
| SCHEMBL3598493 | 0.84 | AR (0.72) | AR | |
| SCHEMBL3611250 | 0.83 | AR (1.00) | AR | |
| SCHEMBL3604981 | 0.83 | AR (1.00) | AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4739682-A1 | 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS | Janssen Pharmaceutica NV (BE) | 2026-05-13 | — | — | EP | disclosed |
| EP-4658653-A1 | IMIDAZO[1,2-D][1,2,4]TRIAZINES AS NLRP3 INHIBITORS | Janssen Pharmaceutica NV (BE) | 2025-12-10 | — | — | EP | disclosed |
| EP-4658654-A1 | PYRROLO[1,2-D][1,2,4]TRIAZINES AND PYRAZOLO[1,5-D] [1,2,4]TRIAZINES AS NLRP3 INHIBITORS | Janssen Pharmaceutica NV (BE) | 2025-12-10 | — | — | EP | disclosed |
| EP-4509122-A2 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND THERAPEUTIC USES THEREOF | Bayer Aktiengesellschaft (DE) | 2025-02-19 | — | — | EP | disclosed |
| US-20250034171-A1 | IMIDAZOPYRIDINE AMIDES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF BACTERIAL INFECTIONS | Janssen Sciences Ireland Unlimited Company (IE) | 2025-01-30 | — | — | US | disclosed |
| WO-2025008058-A1 | 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS | JANSSEN PHARMACEUTICA NV (BE) | 2025-01-09 | — | — | WO | disclosed |
| EP-4135842-B1 | PYRROLO[1,2-D][1,2,4]TRIAZINE-2-YL-ACETAMIDES AS INHIBITORS OF THE NLRP3 INFLAMMASOME PATHWAY | JANSSEN PHARMACEUTICA NV (BE) | 2024-10-23 | — | — | EP | disclosed |
| EP-4188930-B1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND THERAPEUTIC USES THEREOF | BAYER AG (DE) | 2024-10-23 | — | — | EP | disclosed |
| EP-4423097-A1 | IMIDAZOPYRIDINE AMIDES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF BACTERIAL INFECTIONS | Janssen Sciences Ireland Unlimited Company (IE) | 2024-09-04 | — | — | EP | disclosed |
| WO-2024160692-A1 | IMIDAZO[1,2-D][1,2,4]TRIAZINES AS NLRP3 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-08-08 | — | — | WO | disclosed |
| CN-101056845-A | Substituted aniline derivatives | LUNDBECK & CO AS H (DK) | 2007-10-17 | — | — | CN | disclosed |
| US-20070194468-A1 | Method of preparing organomagnesium compounds | LUDWIG-MAXIMILIANS-UNIVERSITAT MUNCHEN (DE) | 2007-08-23 | — | — | US | disclosed |
| EP-1791809-A1 | SUBSTITUTED ANILINE DERIVATIVES | H. LUNDBECK A/S (DK) | 2007-06-06 | — | — | EP | disclosed |
| US-20060155121-A1 | Substituted aniline derivatives | H. LUNDBECK A/S (DK) | 2006-07-13 | — | — | US | disclosed |
| US-20060106067-A1 | Fused benzene derivative and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-05-18 | — | — | US | disclosed |
| WO-2006029623-A1 | SUBSTITUTED ANILINE DERIVATIVES | H. LUNDBECK A/S (DK) | 2006-03-23 | — | — | WO | disclosed |
| US-20050218532-A1 | Method of preparing organomagnesium compounds | LUDWIG-MAXIMILIANS-UNIVERSITAT MUNCHEN (DE) | 2005-10-06 | — | — | US | disclosed |
| EP-1582524-A1 | Method of preparing organomagnesium compounds | Ludwig Maximilians Universität (DE) | 2005-10-05 | — | — | EP | disclosed |
| EP-1582523-A1 | Method of preparing organomagnesium compounds | Ludwig-Maximilians-Universität München (DE) | 2005-10-05 | — | — | EP | disclosed |
| EP-1553074-A1 | FUSED BENZENE DERIVATIVE AND USE | Takeda Pharmaceutical Company Limited (JP) | 2005-07-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106067-A1 | Fused benzene derivative and use | AR, NR5A1, CBR3 | AR 1/4885 |
| US-20070194468-A1 | Method of preparing organomagnesium compounds | SCLY, LIG3, LIG4 | AR 3060/4885 |
| US-20050218532-A1 | Method of preparing organomagnesium compounds | SCLY, LIG3, LIG4 | AR 3060/4885 |
| US-20250034171-A1 | IMIDAZOPYRIDINE AMIDES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF BACTERIAL INFECTIONS | TPMT, QDPR, BRD4 | AR 3946/4885 |
| US-20060155121-A1 | Substituted aniline derivatives | UGT2B7, NAT1, CYP1A2 | AR 182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.